J
Joseph S. Galati
Researcher at Houston Methodist Hospital
Publications - 37
Citations - 3236
Joseph S. Galati is an academic researcher from Houston Methodist Hospital. The author has contributed to research in topics: Ribavirin & Boceprevir. The author has an hindex of 21, co-authored 37 publications receiving 3153 citations. Previous affiliations of Joseph S. Galati include St Lukes Episcopal Hospital & University of Nebraska Medical Center.
Papers
More filters
Journal ArticleDOI
Peginterferon alfa-2b or alfa-2a with ribavirin for treatment of hepatitis C infection.
John G. McHutchison,Eric Lawitz,Mitchell L. Shiffman,Andrew J. Muir,Greg Galler,Jonathan McCone,L. Nyberg,William M. Lee,Reem Ghalib,Eugene R. Schiff,Joseph S. Galati,Bruce R. Bacon,M. Davis,Pabak Mukhopadhyay,Kenneth Koury,Stephanie Noviello,Lisa D. Pedicone,Clifford A. Brass,Janice K. Albrecht,Mark S. Sulkowski +19 more
TL;DR: In patients infected with HCV genotype 1, the rates of sustained virologic response and tolerability did not differ significantly between theTwo available peginterferon-ribavirin regimens or between the two doses of pegin terferon alfa-2b.
Journal ArticleDOI
Efficacy of boceprevir, an NS3 protease inhibitor, in combination with peginterferon alfa-2b and ribavirin in treatment-naive patients with genotype 1 hepatitis C infection (SPRINT-1): an open-label, randomised, multicentre phase 2 trial
Paul Y. Kwo,Eric Lawitz,Jonathan McCone,Eugene R. Schiff,John M. Vierling,David Pound,M. Davis,Joseph S. Galati,Stuart C. Gordon,Natarajan Ravendhran,Lorenzo Rossaro,Frank H. Anderson,Ira M. Jacobson,Raymond A. Rubin,Kenneth Koury,Lisa D. Pedicone,Clifford A. Brass,Eirum Chaudhri,Janice K. Albrecht +18 more
TL;DR: In patients with untreated genotype 1 chronic hepatitis C infection, the addition of the direct-acting antiviral agent boceprevir to standard treatment with peginterferon and ribavirin after a 4-week lead-in seems to have the potential to double the sustained response rate compared with that recorded with standard treatment alone.
Journal ArticleDOI
Effectiveness of Simeprevir Plus Sofosbuvir, with or Without Ribavirin, in Real-World Patients with HCV Genotype 1 Infection
Mark S. Sulkowski,Hugo E. Vargas,Adrian M. Di Bisceglie,Alexander Kuo,K. Rajender Reddy,Joseph K. Lim,Giuseppe Morelli,Jama M. Darling,Jordan J. Feld,Robert S. Brown,Lynn M. Frazier,Thomas G. Stewart,Michael W. Fried,David R. Nelson,Ira M. Jacobson,Nezam H. Afdhal,Imtiaz Alam,Ziv Ben-Ari,J. Bredfeldt,R.S. Brown,R.T. Chung,J. Darling,W. Harlan,A. M. Di Bisceglie,Rolland C. Dickson,H.A. Elbeshbeshy,Gregory T. Everson,Jordan J. Feld,Jonathan M. Fenkel,M.W. Fried,Joseph S. Galati,S.C. Gordon,Mohamed Hassan,T.N. Hawkins,Federico Hinestrosa,I.M. Jacobson,C.A. Kerr,A. Kuo,P. Kwo,Josh Levitsky,J. Lim,A.S. Lok,Mark E. Mailliard,Michael P. Manns,G. Morelli,Andrew J. Muir,D. Nelson,Jacqueline G. O'Leary,Brian L. Pearlman,P. Pockros,Ananthakrishnan Ramani,Nancy Reau,K.R. Reddy,Eugene R. Schiff,Kenneth E. Sherman,Mitchell L. Shiffman,Coleman Smith,J.R. Spivey,Richard K. Sterling,M.S. Sulkowski,Gyongyi Szabo,Norah A. Terrault,C. Trautwein,H.E. Vargas,K. Watts,A. Williams,Stefan Zeuzem +66 more
TL;DR: In a large prospective observational cohort study, a 12-week regimen of simeprevir plus sofosbuvir was associated with high rates of sustained virologic response (SVR) and infrequent treatment discontinuation.
Journal ArticleDOI
Safety and efficacy of current direct-acting antiviral regimens in kidney and liver transplant recipients with hepatitis C: Results from the HCV-TARGET study.
Varun Saxena,Vandana Khungar,Elizabeth C. Verna,Josh Levitsky,Robert S. Brown,Mohamed Hassan,Mark S. Sulkowski,Jacqueline G. O'Leary,Farrukh M. Koraishy,Joseph S. Galati,Alexander Kuo,Monika Vainorius,Lucy Akushevich,David R. Nelson,Michael W. Fried,Norah A. Terrault,K. Rajender Reddy +16 more
TL;DR: In a large prospective observational cohort study, direct‐acting antiviral therapy with SOF/ledipasvir, ombitasvir/paritaprevir/ritonavir + dasabuvir, and SOF plus daclatasvir was efficacious and safe in LT, KT, and DLK transplant recipients; ribavirin did not influence SVR, and graft rejection was rare.
Journal ArticleDOI
The role of choledochoscopy in the diagnosis and management of biliary tract diseases.
Iqbal Siddique,Joseph S. Galati,Victor Ankoma-Sey,R. Patrick Wood,Claire F. Ozaki,Howard Paul Monsour,Isaac Raijman +6 more
TL;DR: Choledochoscopy is a safe and useful endoscopic modality that can provide specific diagnoses and direct treatment in various biliary tract diseases and may change overall patient management and outcome.